OncoMatch/Clinical Trials/NCT07804186
Study of Adjuvant Darovasertib and Crizotinib in Participants With Primary Non-metastatic Uveal Melanoma
Is NCT07804186 recruiting? Yes, currently enrolling (Sep 2026). This Phase 3 trial studies multiple treatments including Darovasertib and Crizotinib (Xalkori) for uveal melanoma.
Treatment: Darovasertib · Crizotinib (Xalkori) — This is a randomized, multi-center, open-label study of adjuvant darovasertib in participants with non-metastatic uveal melanoma (OptimUM-11)
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Melanoma
Disease stage
Required: Stage II, III (AJCC)
classified as high-risk of relapse (AJCC Stage II or Stage 3)
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: primary local therapy — primary uveal melanoma
Completed primary local therapy (enucleation, proton beam therapy, plaque brachytherapy)
Cannot have received: systemic treatment for Uveal Melanoma
Previous systemic treatment for Uveal Melanoma
Lab requirements
Blood counts
Kidney function
Liver function
Cardiac function
Impaired cardiac function [excluded]; history of stroke within the last 6 months of randomization [excluded]
Adequate organ function; Impaired cardiac function; History of stroke within the last 6 months of randomization
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07804186 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
What disease stage is eligible?
Stage II or III is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages